The University of Southampton
University of Southampton Institutional Repository

Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009) : a prospective cohort study

Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009) : a prospective cohort study
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009) : a prospective cohort study

Objectives: evaluation of the safety and humoral immunogenicity of ChAdOx1 nCoV-19 as a fourth dose booster in individuals who have had two initial doses of the vaccine and a third dose of BNT162b2. 

Methods: COV009 is a safety follow-up study of volunteers enroled in the pivotal pre-licensure ChAdOx1 nCoV-19. In this sub-study, 149 eligible participants were given a fourth dose of ChAdOx1 nCoV-19. Primary outcomes were reactogenicity, safety, and humoral immunogenicity. Anti-spike IgG and pseudo-neutralising antibody against multiple variants were measured from pre-first dose to 28 days post-second and post-fourth dose (third dose samples were unavailable). 

Results: a fourth dose of ChAdOx1 nCoV-19 had an acceptable safety profile with no vaccine-related serious adverse events. Humoral responses against various SARS CoV-2 variants post-fourth dose were significantly increased compared with the responses after the second dose (7- to 9-fold increase for anti-spike IgG responses across variants, all p<0.05). Those with lower antibody levels prior to the 4th dose had stronger responses to a 4th dose booster. Seropositivity by anti-nucleocapsid, or higher antibody responses pre-fourth dose correlated with lower infection risks six months thereafter (OR: 0.16, 95% CI: 0.05, 0.50).

Conclusions: the ChAdOx1 nCoV-19 fourth dose is well tolerated and boosts humoral immunity; this was evident as an increased humoral response across multiple variants of concern. These data support its use as a booster dose against SARS-CoV-2 infection.

ChAdOx1 nCoV-19, COVID-19 vaccine, Fourth Dose, Immunogenicity, Safety
0163-4453
Feng, Shuo
7bed8cb4-d66f-4ef1-b3fb-f9cc0c996be4
Bibi, Sagida
bd84c45a-68e3-47a1-b5ea-20b41042e9bf
Aley, Parvinder K.
47682c89-e7f3-481a-9176-23bb4053ba36
Cappuccini, Federica
0622e2a3-3cd8-4398-99ea-8b09d59366f1
Clutterbuck, Elizabeth A.
db4945e9-ca8e-44f8-8030-4c0160956e71
Conlin, Kerry
d91dde19-9a9f-490a-9f0e-fca429623c64
Ebrahimi, Narges
f9a077b3-ebf4-4cde-81e4-52650cf25983
Eordogh, Agnes
9859a6e8-3047-4058-929d-59bc32dcf9af
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Felle, Sally
666ade50-8f91-410e-a642-03f85dfdbd2c
Green, Justin
37bbdc41-4756-4c59-b0a7-4fde0731407f
Gill, Hardeep
63296dde-b059-4f16-942a-9b8e4bfee0d4
Mujadidi, Yama
bffb5a37-2ab0-4883-9001-c00b4e996c8c
Oladunjoye, Iyiola
2e42bb18-0cbe-41e9-b3da-68f1547b30af
Owino, Nelly
29d5f128-88c2-43e0-8890-3f925944b6a7
Plested, Emma
7af2cc98-f996-4bca-bfab-ff02982a9780
Robinson, Hannah
5db3b2f0-c4a0-4cf3-a0e7-11a85972e000
Stuart, Arabella
33deeaa1-85ee-45fd-8074-2f63012b6f8d
Voysey, Merryn
fd9bd72b-7aaf-4390-a27f-bd8a6e6d92ae
Pollard, Andrew J.
36960941-fef0-4293-9bcc-9028588b929b
Lambe, Teresa
d5fd6770-9ef0-45a9-a23a-9a7d865009a6
et al.
Feng, Shuo
7bed8cb4-d66f-4ef1-b3fb-f9cc0c996be4
Bibi, Sagida
bd84c45a-68e3-47a1-b5ea-20b41042e9bf
Aley, Parvinder K.
47682c89-e7f3-481a-9176-23bb4053ba36
Cappuccini, Federica
0622e2a3-3cd8-4398-99ea-8b09d59366f1
Clutterbuck, Elizabeth A.
db4945e9-ca8e-44f8-8030-4c0160956e71
Conlin, Kerry
d91dde19-9a9f-490a-9f0e-fca429623c64
Ebrahimi, Narges
f9a077b3-ebf4-4cde-81e4-52650cf25983
Eordogh, Agnes
9859a6e8-3047-4058-929d-59bc32dcf9af
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Felle, Sally
666ade50-8f91-410e-a642-03f85dfdbd2c
Green, Justin
37bbdc41-4756-4c59-b0a7-4fde0731407f
Gill, Hardeep
63296dde-b059-4f16-942a-9b8e4bfee0d4
Mujadidi, Yama
bffb5a37-2ab0-4883-9001-c00b4e996c8c
Oladunjoye, Iyiola
2e42bb18-0cbe-41e9-b3da-68f1547b30af
Owino, Nelly
29d5f128-88c2-43e0-8890-3f925944b6a7
Plested, Emma
7af2cc98-f996-4bca-bfab-ff02982a9780
Robinson, Hannah
5db3b2f0-c4a0-4cf3-a0e7-11a85972e000
Stuart, Arabella
33deeaa1-85ee-45fd-8074-2f63012b6f8d
Voysey, Merryn
fd9bd72b-7aaf-4390-a27f-bd8a6e6d92ae
Pollard, Andrew J.
36960941-fef0-4293-9bcc-9028588b929b
Lambe, Teresa
d5fd6770-9ef0-45a9-a23a-9a7d865009a6

Feng, Shuo, Bibi, Sagida and Aley, Parvinder K. , et al. (2025) Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009) : a prospective cohort study. Journal of Infection, 90 (2), [106423]. (doi:10.1016/j.jinf.2025.106423).

Record type: Article

Abstract

Objectives: evaluation of the safety and humoral immunogenicity of ChAdOx1 nCoV-19 as a fourth dose booster in individuals who have had two initial doses of the vaccine and a third dose of BNT162b2. 

Methods: COV009 is a safety follow-up study of volunteers enroled in the pivotal pre-licensure ChAdOx1 nCoV-19. In this sub-study, 149 eligible participants were given a fourth dose of ChAdOx1 nCoV-19. Primary outcomes were reactogenicity, safety, and humoral immunogenicity. Anti-spike IgG and pseudo-neutralising antibody against multiple variants were measured from pre-first dose to 28 days post-second and post-fourth dose (third dose samples were unavailable). 

Results: a fourth dose of ChAdOx1 nCoV-19 had an acceptable safety profile with no vaccine-related serious adverse events. Humoral responses against various SARS CoV-2 variants post-fourth dose were significantly increased compared with the responses after the second dose (7- to 9-fold increase for anti-spike IgG responses across variants, all p<0.05). Those with lower antibody levels prior to the 4th dose had stronger responses to a 4th dose booster. Seropositivity by anti-nucleocapsid, or higher antibody responses pre-fourth dose correlated with lower infection risks six months thereafter (OR: 0.16, 95% CI: 0.05, 0.50).

Conclusions: the ChAdOx1 nCoV-19 fourth dose is well tolerated and boosts humoral immunity; this was evident as an increased humoral response across multiple variants of concern. These data support its use as a booster dose against SARS-CoV-2 infection.

Text
1-s2.0-S0163445325000179-main - Version of Record
Available under License Creative Commons Attribution.
Download (5MB)

More information

Accepted/In Press date: 13 January 2025
e-pub ahead of print date: 16 January 2025
Published date: 21 January 2025
Keywords: ChAdOx1 nCoV-19, COVID-19 vaccine, Fourth Dose, Immunogenicity, Safety

Identifiers

Local EPrints ID: 498506
URI: http://eprints.soton.ac.uk/id/eprint/498506
ISSN: 0163-4453
PURE UUID: 293fa639-ccc9-41d2-a6a2-59fc0bd390c3
ORCID for Saul N. Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 20 Feb 2025 17:40
Last modified: 22 Aug 2025 01:56

Export record

Altmetrics

Contributors

Author: Shuo Feng
Author: Sagida Bibi
Author: Parvinder K. Aley
Author: Federica Cappuccini
Author: Elizabeth A. Clutterbuck
Author: Kerry Conlin
Author: Narges Ebrahimi
Author: Agnes Eordogh
Author: Saul N. Faust ORCID iD
Author: Sally Felle
Author: Justin Green
Author: Hardeep Gill
Author: Yama Mujadidi
Author: Iyiola Oladunjoye
Author: Nelly Owino
Author: Emma Plested
Author: Hannah Robinson
Author: Arabella Stuart
Author: Merryn Voysey
Author: Andrew J. Pollard
Author: Teresa Lambe
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×